Psychedelics
Ketamine One’s KGK Science Acquisition Provides Numerous Benefits
KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MYO) (“Ketamine One” or the “Company”), a North American leader in mental health treatments with a growing network of clinics, recently announced that its newly acquired and wholly-owned subsidiary, KGK Science, has over US$2.3 million in net new revenue being secured from the month of July, […]
Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research Hospital Medicinal mushroom compound with anticancer activities that have minimal effects on normal cells Showed superior potency against aggressive breast cancer with potential to treat aggressive malignancies such as triple negative and inflammatory breast cancers Advancing IND-enabling studies for FDA clinical trials […]
TORONTO, Aug. 18, 2021 /CNW/ – Wake Network, Inc. (“Wake” or the “Company“), a global leader in naturally-derived psilocybin production and the developer of genomics-based integration therapies, is pleased to announce that MagicBio Research Inc. (“MagicBio“), a wholly-owned subsidiary of Wake, has received an exemption from Health Canada to carry out laboratory research on the biosynthesis process of […]
Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders
NAPLES, Fla., Aug. 18, 2021 /PRNewswire/ — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel therapeutic drugs to improve the quality of life for cancer patients, Chief Executive Officer, David Johnson, today is issuing an open letter to shareholders. Dear Fellow Shareholders: As we approach our annual stockholder meeting on September 14, 2021 and the expected closing of the […]
Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin
TORONTO, Aug. 17, 2021 /CNW/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, is pleased to announce that it has received a No Objection Letter from Health Canada, allowing Diamond to proceed with a human clinical trial to evaluate low doses […]
Silo Pharma Secures Patent that May be Used for Psychedelics Delivery Technology
Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Silo Pharma Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Patent Office issued a notice of allowance for its technology/method patent covering an isolated homing […]
Ketamine One Subsidiary KGK Science Secures Multiple New Contracts
Over US$2.3 Million of Net Revenue Being Negotiated and Secured as Backlog of Paused Opportunities Begins to be Formalized VANCOUVER, British Columbia, Aug. 16, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in […]
Upsized and oversubscribed Series B financing brings healthcare and science focused venture capital Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in other neuro-psychiatric indications OXFORD, England–(BUSINESS WIRE)–Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced […]
OMID Makes Strategic Investment Into Psychedelic Medicine
ALPHA, N.J., Aug. 12, 2021 /PRNewswire/ — Today, OMID Holdings, Inc. (OTC Pink: OMID) is pleased to announce its initial investment to gain exposure to the legal psychedelic medicine industry. The investment made in the second quarter with KetaMD, which offers at-home medical ketamine treatments, marks the beginning of OMID’s entry into another form of early-stage legal alternative […]
BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences (Revixia), a wholly owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental health disorders. Derived from Salvia divinorum, SalA is a unique […]
Proprietary computer vision technology will provide the Ehave Dashboard and Ehave Medical App with the ability to extract information about changes in light absorption on an individual’s facial skin that is reflective of their physiological condition MIAMI, Aug. 11, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics […]
LANGLEY, BC / ACCESSWIRE / August 11, 2021 / Phyto Extractions Inc. (formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX)(FRA:D2EP) (“Phyto Extractions™” or the “Company”) is pleased to announce that it has entered into a share purchase agreement dated August 10, 2021 (the “Share Purchase Agreement”) pursuant to which the Company has agreed to acquire, indirectly through its […]
Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control. […]
Proprietary computer vision technology will provide the Ehave Dashboard and Ehave Medical App with the ability to extract information about changes in light absorption on an individual’s facial skin that is reflective of their physiological condition MIAMI, Aug. 11, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics […]
The psychedelic renaissance has taken the research community by storm, but psilocybin, DMT, MDMA, and other therapies remain in development. Ketamine is the only widely available psychedelic therapy that the FDA approves to treat depression and suicidal ideations. As a result, investors may want to start there for near-term opportunities. Let’s take a look at […]
Calgary, Alberta – TheNewswire -August 10, 2021 – (CNSX:MXT.CN) (OTC:MSTTE) “Computers are fast, accurate and stupid. Humans are slow, inaccurate and brilliant. Together they are powerful beyond imagination” – Albert Einstein The Corporation reports that it’s contracted medical professionals (see bios below) have begun generating a series of Digital Opinions (“DOs”) based on their professional experience and education. Creating these DOs […]
Professor Sammis takes sabbatical to devote significant time toward developing psilocybin and cannabis intellectual property (IP) for Delic Labs VANCOUVER, BC, Aug. 10, 2021 /PRNewswire/ – Delic Corp Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced Professor Glenn Sammis, Scientific Advisor of its subsidiary Delic Labs has been granted a full professorship at the University […]
Wuhan General Group Updates on Third Scientific Paper Published on Psychedelics
CAPE TOWN, SA / ACCESSWIRE / August 5, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update: The research team funded by Wuhan General Group has successfully published a third paper on […]
Calgary, Alberta–(Newsfile Corp. – August 5, 2021) – Psygen Industries Ltd. (“Psygen” or the “Company”) announced today that it has closed its previously announced non-brokered private placement financing (the “Offering”) of unsecured convertible debentures (the “Debentures”) for gross proceeds of $5.5 million. The Debentures incur interest of 8.0% per annum. The proceeds will allow Psygen to hire key […]
Unlocking the potential of psychedelics, including DMT, and other tryptamines to treat the significant unmet medical needs of glaucoma patients Partnering with world-renowned research institution brings validated drug delivery expertise in novel, controlled drug-release technologies Toronto, Ontario–(Newsfile Corp. – August 5, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), […]
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis
Focusing on becoming a global leader in prescription-based ketamine products Advancing to a Phase 2 clinical study in the U.S. TORONTO, Aug. 04, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration […]
Agreement Provides Ketamine One With First-of-its-Kind VR Scent Capabilities to Generate More Realistic Immersive Experiences and Help Improve Patient Treatment Outcomes Vancouver, British Columbia, August 4, 2021 / Globe Newswire / – KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and […]
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB: CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced overnight marketed offering (the “Offering”) including the exercise in full of the over-allotment option granted to the Underwriters (as defined herein). In connection with the Offering, the […]
Medxtractor Doubles Down on B2B Licensing & mHealth
Medxtractor Corp. (CSE: MXT) (OTCQB: MXTTF) is known for its award-winning extraction equipment, but recently, the company refocused its efforts on its proprietary health-related databases, machine learning analysis, and plans to engage in B2B licensing and mHealth. Mental health disorders are notoriously difficult to diagnose and treat. Unlike most other ailments, there isn’t a simple […]
Bionomics Announces Plans to Conduct U.S. Initial Public Offering
ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United States and a concurrent listing of ADSs on Nasdaq. The number of ADSs and price […]
Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols Vancouver, British Columbia–(Newsfile Corp. – July 30, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a […]
New CBD Trials Point the Way for Enveric, MagicMed
As the cannabis industry strives to gain widespread acceptance in the mainstream, scientific studies into the potential benefits of the plant and its active ingredients play a key role in reaching that goal. There are currently very few approved pharmaceutical drug applications for cannabinoids, but that could change. After decades of effective prohibition there […]
Health Canada Dealer’s License to allow the possession, production, and delivery of all controlled natural psychedelic substances VANCOUVER, BC , July 29, 2021 /CNW/ – Filament Health Corp. (NEO: FH) (“Filament” or the “Company”), a global leader in natural psychedelic drug development, has been granted an amendment to its existing Health Canada Dealer’s License, amplifying the Company’s position at the […]
Levitee Labs Acquires Five Addiction Clinics in Alberta
Levitee acquires the majority of the operating assets of ACT Medical Centres Inc. Five acquired addiction clinics have conducted 35,000+ patient visits over last 12 months Clinics will be integrated with Levitee’s growing portfolio of healthcare assets VANCOUVER, BC, July 29, 2021 /CNW/ – Levitee Labs Inc. (CSE: LVT) (the “Company” or “Levitee”), an integrative wellness company with a diversified […]
Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics
VANCOUVER, BC, July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announced it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of psilocybin and […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
ICC International Cannabis’ corporate mandate is to plan, design, build and operate the highest quality, lowest cost Cannabis production, processing and distribution facilities worldwide.
Potnetwork Holdings, Inc. has two wholly owned subsidiaries, PotNetwork Inc. and Sunrise Auto Mall Inc.. PotNetwork is positioned to be the premier worldwide news and content provider for the Cannabis industry, and is developing into a 24/7 network.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
